Mesoblast Ltd. (NASDAQ:MESO) shares gapped up prior to trading on Tuesday . The stock had previously closed at $4.17, but opened at $4.28. Mesoblast shares last traded at $4.75, with a volume of 35,001 shares traded.

Several research analysts recently commented on the company. Maxim Group reiterated a “buy” rating on shares of Mesoblast in a research report on Saturday, June 4th. Credit Suisse Group AG lowered Mesoblast from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $10.00 to $5.00 in a research report on Tuesday, June 14th. Finally, Zacks Investment Research lowered Mesoblast from a “buy” rating to a “sell” rating in a research report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $9.10.

The stock’s 50-day moving average is $4.14 and its 200 day moving average is $6.60. The firm’s market capitalization is $373.35 million.

Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.